RxDoctor Payments Data

Joseph Kipp, MD

Family Medicine · Newtown, PANPI 1154331452

Payments from drug & device makers

$12,600in general payments, 2019–2025

Across 762 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • GSK$816
  • Lilly USA, LLC$698
  • Astellas Pharma US Inc$585
  • plus $7K from 51 others

What the payments were for

  • Food & beverage$12,53599%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)111$1,633
AstraZeneca(2 entities)71$1,230
Novo Nordisk75$1,131
GSK47$816
Lilly USA, LLC41$698
Astellas Pharma US Inc34$585
Sumitomo Pharma America, Inc.26$548
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC44$531
Pfizer38$478
Merck25$423
Otsuka America Pharmaceutical, Inc.22$413
Esperion Therapeutics, Inc.19$339
Boehringer Ingelheim18$325
Gilead12$280
Exact Sciences14$272
Abbott12$251
Corium, LLC10$216
Takeda Pharmaceuticals U.S.A., Inc.12$180
Amgen12$177
Dexcom, Inc.6$130
Amarin Pharma, Inc.9$127
Johnson & Johnson5$102
Axsome Therapeutics, Inc.5$97
Lundbeck LLC5$95
E.r. Squibb & Sons, L.L.C.7$90
Tolmar, Inc.5$88
Biohaven Pharmaceutical Holding Company Ltd.5$87
Corcept Therapeutics4$86
Kowa Pharmaceuticals America, Inc.7$86
Biohaven Pharmaceuticals, Inc.5$84
Bayer4$76
Idorsia Pharmaceuticals US Inc4$72
Sunovion Pharmaceuticals Inc.4$72
Jazz Pharmaceuticals Inc.3$71
Paratek Pharmaceuticals, Inc.4$67
Teva Pharmaceuticals USA, Inc.4$57
Verity Pharmaceuticals Inc.3$55
Kaleo, Inc.4$54
Shield Therapeutics Inc1$54
Tris Pharma Inc3$51
Ironshore Pharmaceuticals Inc.2$42
Genentech USA, Inc.2$35
Avanir Pharmaceuticals, Inc.2$34
Novartis2$32
Sanofi Pasteur Inc.1$25
Aytu Biopharma, Inc.2$24
Inspire Medical Systems, Inc.1$24
Impel Pharmaceuticals Inc.1$22
Phathom Pharmaceuticals, Inc.1$20
Scilex Pharmaceuticals Inc.1$19
Si-bone, Inc.1$18
Radius Health, Inc.1$16
Linus Health, Inc.1$14
Adlon Therapeutics L.p.1$13
GRT US Holding, Inc.1$13
Bausch & Lomb, A Division Of Bausch Health US, LLC1$12
Theracosbio, LLC1$10

How this compares

$12,600 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$267,693
Medicare patients
782
Services billed
5,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol100$101,216
EliquisApixaban67$84,706
OzempicSemaglutide48$57,563
JardianceEmpagliflozin48$51,139
RybelsusSemaglutide20$37,989
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$30,264
MounjaroTirzepatide29$29,926
Janumet XrSitagliptin Phos/Metformin Hcl23$28,858
JanuviaSitagliptin Phosphate21$22,445
MyrbetriqMirabegron21$20,930
GemtesaVibegron12$15,517
Emgality PenGalcanezumab-Gnlm17$13,949
XareltoRivaroxaban15$12,675
InvokametCanagliflozin/Metformin Hcl13$7,171
Oxycodone Hcl187$6,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,230$101,216100 claims
Novo NordiskOzempic, Rybelsus$1,131$95,55268 claims
PfizerEliquis, Paxlovid$478$87,564111 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$325$62,84272 claims
MerckJanumet Xr, Januvia, Lagevrio (Eua)$423$55,21655 claims
GSKTrelegy Ellipta$816$30,26430 claims
Lilly USA, LLCMounjaro$698$29,92629 claims
Astellas Pharma US IncMyrbetriq$585$20,93021 claims
Johnson & JohnsonXarelto, Invokamet$102$19,84628 claims
Sumitomo Pharma America, Inc.Gemtesa$548$15,51712 claims
AbbVieSynthroid$1,633$4,61566 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Newtown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →